Dynamic immune cell profiling identified natural killer cell shift as the key event in early allograft dysfunction after liver transplantation

Abstract

Early allograft dysfunction (EAD) is a life-threatening and fast-developing complication after liver transplantation. The underlying mechanism needs to be better understood, and there has yet to be an efficient therapeutic target. This study retrospectively reviewed 109 patients undergoing liver transplantation, with dynamic profiling of CD3/4/8/16/19/45/56 on the peripheral immune cells (before transplant and 2–4 days after). Altogether, 35 out of the 109 patients developed EAD after liver transplantation. We observed a significant decrease in the natural killer cell proportion (NK cell shift, p = 0.008). The NK cell shift was linearly correlated with cold ischemic time (p = 0.016) and was potentially related to the recipients' outcomes. In mouse models, ischemic/reperfusion (I/R) treatments induced the recruitment of NK cells from peripheral blood into liver tissues. NK cell depletion blocked a series of immune cascades (including CD8+ CD127+ T cells) and inhibited hepatocyte injury effectively in I/R and liver transplantation models. We further found that I/R treatment increased hepatic expression of the ligands for natural killer group 2 member D (NKG2D), a primary activating cell surface receptor in NK cells. Blockade of NKG2D showed a similar protective effect against I/R injury, indicating its role in NK cell activation and the subsequent immunological injury. Our findings built a bridge for the translation from innate immune response to EAD at the bedside. Peripheral NK cell shift is associated with the incidence of EAD after liver transplantation. NKG2D-mediated NK cell activation is a potential therapeutic target.

References

[1] Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischaemia-reperfusion injury in liver transplantation—from bench to bedside. Nat Rev Gastroenterol Hepatol. 2013;10(2):79-89.

[2] Wang P, Jiang Z, Wang C, et al. Immune tolerance induction using cell-based strategies in liver transplantation: clinical perspectives. Front Immunol. 2020;11:1723.

[3] Agopian VG, Harlander-Locke MP, Markovic D, et al. Evaluation of early allograft function using the liver graft assessment following transplantation risk score model. JAMA Surg. 2018;153(5):436-444.

[4] Hudcova J, Scopa C, Rashid J, Waqas A, Ruthazer R, Schumann R. Effect of early allograft dysfunction on outcomes following liver transplantation. Clin Transpl. 2017;31(2).

[5] Croome KP, Lee DD, Keaveny AP, Taner CB. Noneligible donors as a strategy to decrease the organ shortage. Am J Transplant. 2017;17(6):1649-1655.

[6] Lee DD, Singh A, Burns JM, Perry DK, Nguyen JH, Taner CB. Early allograft dysfunction in liver transplantation with donation after cardiac death donors results in inferior survival. Liver Transpl. 2014;20(12):1447-1453.

[7] Heerwagen C, Schuster M, Bornscheurer A, et al. Rapid exchange of large numbers of donor- and host leukocytes after human liver transplantation. Transpl Int. 2001;14(4):240-247.

[8] Moroso V, Metselaar HJ, Mancham S, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl. 2010;16(7):895-908.

[9] Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949.

[10] Pandya K, Sastry V, Panlilio MT, et al. Differential impact of extended criteria donors after brain death or circulatory death in adult liver transplantation. Liver Transpl. 2020;26(12):1603-1617.

[11] Jassem W, Xystrakis E, Ghnewa YG, et al. Normothermic machine perfusion (NMP) inhibits proinflammatory responses in the liver and promotes regeneration. Hepatology. 2019;70(2):682-695.

[12] Yamagiwa S, Kamimura H, Ichida T. Natural killer cell receptors and their ligands in liver diseases. Med Mol Morphol. 2009;42(1):1-8.

[13] Peng H, Wisse E, Tian Z. Liver natural killer cells: subsets and roles in liver immunity. Cell Mol Immunol. 2016;13(3):328-336.

[14] Obara H, Nagasaki K, Hsieh CL, et al. IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. Am J Transplant. 2005;5(9):2094-2103.

[15] Wang K, Lu D, Liu Y, et al. Severity of early allograft dysfunction following donation after circulatory death liver transplantation: a multicentre study. Hepatobiliary Surg Nutr. 2021;10(1):9-19.

[16] Robin F, Khene ZE, Livin M, et al. Radiomic analysis of liver grafts from brain-dead donors can predict early allograft dysfunction following transplantation: a proof-of-concept study. HPB (Oxford). 2022;24(9):1527-1534.

[17] He YB, Sun JS, Wang ZP, et al. Risk factors of early liver dysfunction after liver transplantation using grafts from donation after citizen death donors. Transpl Immunol. 2022;71:101525.

[18] Wang XW, Guo RD, Ma JG, Wang YW, Zou XF. Effects of prolonged cold ischemia on the DCD kidney function and Inflammasome expression in rat kidney transplants. Transpl Immunol. 2022;74:101511.

[19] Ali JM, Davies SE, Brais RJ, et al. Analysis of ischemia/reperfusion injury in time-zero biopsies predicts liver allograft outcomes. Liver Transpl. 2015;21(4):487-499.

[20] Zhou H, Zhou S, Shi Y, et al. TGR5/Cathepsin E signaling regulates macrophage innate immune activation in liver ischemia and reperfusion injury. Am J Transplant. 2020;104:S165.

[21] Fahrner R, Dondorf F, Ardelt M, Settmacher U, Rauchfuss F. Role of NK, NKT cells and macrophages in liver transplantation. World J Gastroenterol. 2016;22(27):6135-6144.

[22] Kimura S, Ozaki KS, Ueki S, et al. Contribution of alloantigens to hepatic ischemia/reperfusion injury: roles of natural killer cells and innate immune recognition of nonself. Liver Transpl. 2016;22(1):80-90.

[23] Zhuang Q, Lakkis FG. Dendritic cells and innate immunity in kidney transplantation. Kidney Int. 2015;87(4):712-718.

[24] Calabrese DR, Aminian E, Mallavia B, et al. Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury. J Clin Invest. 2021;131(3):e137047.

[25] Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734-738.

[26] Mai HL, Nguyen TVH, Bouchaud G, et al. Targeting the interleukin-7 receptor alpha by an anti-CD127 monoclonal antibody improves allergic airway inflammation in mice. Clin Exp Allergy. 2020;50(7):824-834.

[27] Hartgring SA, Willis CR, Alcorn D, et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 2010;62(9):2716-2725.

[28] Johnson CB, Riesenberg BP, May BR, et al. Effector CD8+ T-cell engraftment and antitumor immunity in lymphodepleted hosts is IL7Ralpha dependent. Cancer Immunol Res. 2015;3(12):1364-1374.

[29] Melsen JE, Lugthart G, Lankester AC, Schilham MW. Human circulating and tissue-resident CD56(bright) natural killer cell populations. Front Immunol. 2016;7:262.

[30] Zimmerman MA, Martin A, Yee J, Schiller J, Hong JC. Natural killer T cells in liver ischemia-reperfusion injury. J Clin Med. 2017;6(4):41.

[31] Shen K, Zheng SS, Park O, Wang H, Sun Z, Gao B. Activation of innate immunity (NK/IFN-gamma) in rat allogeneic liver transplantation: contribution to liver injury and suppression of hepatocyte proliferation. Am J Physiol Gastrointest Liver Physiol. 2008;294(4):G1070-G1077.

[32] Zhang X, Zhuang R, Ye Q, et al. High expression of human AugminComplex submit 3 indicates poor prognosis and associates with tumor progression in hepatocellular carcinoma. J Cancer. 2019;10(6):1434-1443.

[33] Han X, Wang Y, Sun J, et al. Role of CXCR3 signaling in response to anti-PD-1 therapy. EBioMedicine. 2019;48:169-177.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.